Breast surgery for low-grade ductal carcinoma may not improve survival
the ONA take:
According to a new study published in JAMA Surgery, researchers from Brigham and Women's Hospital in Boston, Massachusetts, have found that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) experienced no difference in survival compared with those who did not receive surgery.
For the retrospective analysis, researchers analyzed data from over 50,000 cases of DCIS available from the Surveillance, Epidemiology and End Results (SEER) database between 1998 and 2011. All patients were treated at Dana-Farber/Brigham and Women's Cancer Center.
Results showed that patients with low-grade DCIS who did not receive surgery at or shortly after diagnosis had a 10-year survival rate of 98.8% compared with 98.6% for those who did receive surgery; however, women with intermediate- or high-grade DCIS, the survival rate was significantly higher for those who had surgery versus those who did not.
The researchers note that a prospective clinical trial is warranted before it can be concluded that breast surgery should be avoided for women with low-grade DCIS.
Breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ experienced no difference in survival.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|